Cardiovascular safety trials: Be careful what you wish for

Journal of Diabetes

Volumn 6, Issue 1, 2014, Pages 1-3

  Bloomgarden, Zachary ^a   Grunberger, George ^b  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b Grunberger Diabetes Institute   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALOGLIPTIN; ANTIDIABETIC AGENT; HEMOGLOBIN A1C; PLACEBO; SAXAGLIPTIN;

CARDIOVASCULAR RISK; CARDIOVASCULAR SYSTEM; CLINICAL TRIAL (TOPIC); DIABETES MELLITUS; DRUG SAFETY; EDITORIAL; GLYCEMIC CONTROL; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPOGLYCEMIA; KIDNEY DISEASE; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); TREATMENT OUTCOME;

CARDIOVASCULAR DISEASES; CLINICAL TRIALS AS TOPIC; DIABETES MELLITUS; HUMANS; HYPOGLYCEMIC AGENTS;

EID: 84889670361     PISSN: 17530393     EISSN: 17530407     Source Type: Journal    
DOI: 10.1111/1753-0407.12092     Document Type: Editorial

References (16)

1. Budnitz DS, Lovegrove MC, Shehab N, Richards CL. Emergency hospitalizations for adverse drug events in older Americans. N Engl J Med. 2011; 365: 2002-2012.
2. Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med. 2007; 356: 2457-2471.
3. Bloomgarden ZT. The Avandia debate. Diabetes Care. 2007; 30: 2401-2408.
4. The Endocrine Society: The Endocrine Society statement to providers on the report published in the New England Journal of Medicine on Avandia. 2007. Available from: http://www.endosociety.org/publicpolicy/policy/avandia.cfm (accessed 11 July 2007).
5. US Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER). Guidance for industry diabetes mellitus: Evaluating cardiovascular risk in new antidiabetic therapies to treat type 2 diabetes. Available from: http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm071627.pdf (accessed 15 September 2013).
6. Bloomgarden ZT. Diabetes treatment. Diabetes Care. 2009; 32: e25-30.
7. Scirica BM, Bhatt DL, Braunwald E etal. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med. 2013; 369: 1317-1326.
8. White WB, Cannon CP, Heller SR etal. Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N Engl J Med. 2013; 369: 1327-1335.
9. O'Riordan M. Saxagliptin, alogliptin neither help nor harm CV risk in diabetics. Available from: http://www.theheart.org/article/1577109.do (accessed 14 September 2013).
10. Hursten L. Cardiovascular outcome studies in diabetes drugs finally arrive. Available from: http://www.forbes.com/sites/larryhusten/2013/09/02/cardiovascular-outcome-studies-in-diabetes-drugs-finally-arrive/ (accessed 14 September 2013).
11. Bloomgarden ZT. Glycemic control in diabetes: A tale of three studies. Diabetes Care. 2008; 31: 1913-1919.
12. Sanofi. Sanofi provides update on lixisenatide new drug application in US [press release]. Available from: http://en.sanofi.com/Images/33756_20130912_lixisenatide_en.pdf (accessed 15 September 2013).
13. Tucker ME. FDA panel endorses insulin degludec. Medscape Medical News, 9 Nov 2012. Available from: http://www.medscape.com/viewarticle/774198 (accessed 14 September 2013).
14. Gough SC, Bhargava A, Jain R, Mersebach H, Rasmussen S, Bergenstal RM. Low-volume insulin degludec 200 units/mL once daily improves glycemic control similarly to insulin glargine with a low risk of hypoglycemia in insulin-naive patients with type 2 diabetes: A 26-week, randomized, controlled, multinational, treat-to-target trial: The BEGIN LOW VOLUME trial. Diabetes Care. 2013; 36: 2536-2542.
15. Heise T, Tack CJ, Cuddihy R etal. A new-generation ultra-long-acting basal insulin with a bolus boost compared with insulin glargine in insulin-naive people with type 2 diabetes: A randomized, controlled trial. Diabetes Care. 2011; 34: 669-674.
16. Bloomgarden ZT, Einhorn D. Hypoglycemia in type 2 diabetes: Current controversies and changing practices. Front Endocrinol. 2012; 3: 66.